九典制藥(300705.SZ)上半年淨利2852.07萬元同比增2.17%
格隆匯8月19日丨九典制藥(300705.SZ)披露2019年半年度報告，報告期內公司實現營業收入4.26億元，同比增長18.19%；歸屬於上市公司股東的淨利潤2852.07萬元，同比增長2.17%；經營活動現金淨流出246.35萬元，而上年同期為淨流入335.87萬元；基本每股收益0.12元，加權平均淨資產收益率3.90%。
報告期末，公司總資產9.70億元，較上年度末增長2.79%；歸屬於上市公司股東的淨資產7.36億元，較上年度末增長2.44%。
報告期內，醫藥行業監管日趨嚴格，行業政策頻出，市場競爭激烈，圍繞2019年年度經營計劃，公司持續完善內部管理，健全內部控制，不斷的推進新產品研發和技術創新，狠抓安全生產和環保管理，強化質量管理，進一步加強市場開拓力度，積極推進公司品牌建設，在全體員工團結拼搏，努力奮鬥下，公司持續穩健運營，總體經營情況良好。
1、市場營銷方面。持續打造更加專業、高效的銷售團隊，團隊建設工作收效明顯；加強營銷體系建設與學術推廣，產品招標工作開展順利；強化品牌建設，加大媒體宣傳力度，提升品牌形象，深入開發終端市場。
2、研發與技術創新方面。報告期內，公司持續加大研發投入，加強技術創新，通過仿製藥質量與療效一致性評價品種1個，完成原料藥備案品種1個，獲准開展臨牀試驗品種1個，另外還完成了2個一致性評價品種的BE研究，5個原料藥品種完成工藝驗證，1個仿製藥4類品種的申報等。同時新授權發明專利1項，提交發明專利申請7項。
3、安全生產和質量管理方面。報告期內，公司合理安排生產，不斷提高生產效率，及時完成生產任務，確保銷售發貨；開展了2次安全及消防培訓和演練，未發生重大安全事故；同時深化GMP管理，加強全面質量管理，確保產品質量。報告期內公司共通過3次GMP認證檢查並獲得認證證書。
4、內控完善方面。為持續完善內部管理，進一步健全內部控制，公司組織開展了對各層級、各業務環節的內控管理制度的全面梳理工作，對已有制度與現在公司實際情況的適應性進行評估並修改完善，同時查漏補缺，完善內控體系建設，公司規範治理工作水平進一步提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
